Bio-Genex Laboratories, Inc.
Bio-Genex Laboratories, Inc. (BGNX) Stock Competitors & Peer Comparison
See (BGNX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BGNX | $0.00 | -96.77% | 0 | N/A | N/A | N/A |
| LZAGY | $69.23 | +2.18% | 49.3B | 41.47 | $1.67 | +0.62% |
| WUXAY | $16.95 | +7.61% | 48.4B | 17.47 | $0.97 | +1.08% |
| LZAGF | $665.65 | -2.54% | 47.1B | 40.82 | $16.44 | +0.35% |
| WUXIF | $13.88 | +0.00% | 41.4B | 14.31 | $0.97 | +1.68% |
| ERFSF | $80.52 | +0.66% | 14.1B | 26.93 | $2.99 | +0.85% |
| BMXMF | $105.41 | +0.00% | 12.4B | 27.10 | $3.89 | +0.98% |
| SKHHY | $14.92 | +2.05% | 7.4B | 19.17 | $0.78 | +4.91% |
| SKHCF | $14.58 | +4.11% | 7.2B | 19.70 | $0.74 | +4.99% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
Stock Comparison
BGNX vs LZAGY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, LZAGY has a market cap of 49.3B. Regarding current trading prices, BGNX is priced at $0.00, while LZAGY trades at $69.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas LZAGY's P/E ratio is 41.47. In terms of profitability, BGNX's ROE is N/A, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, BGNX is less volatile compared to LZAGY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check LZAGY's competition here
BGNX vs WUXAY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, WUXAY has a market cap of 48.4B. Regarding current trading prices, BGNX is priced at $0.00, while WUXAY trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas WUXAY's P/E ratio is 17.47. In terms of profitability, BGNX's ROE is N/A, compared to WUXAY's ROE of +0.28%. Regarding short-term risk, BGNX is less volatile compared to WUXAY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check WUXAY's competition here
BGNX vs LZAGF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, LZAGF has a market cap of 47.1B. Regarding current trading prices, BGNX is priced at $0.00, while LZAGF trades at $665.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas LZAGF's P/E ratio is 40.82. In terms of profitability, BGNX's ROE is N/A, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, BGNX is less volatile compared to LZAGF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check LZAGF's competition here
BGNX vs WUXIF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, BGNX is priced at $0.00, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas WUXIF's P/E ratio is 14.31. In terms of profitability, BGNX's ROE is N/A, compared to WUXIF's ROE of +0.28%. Regarding short-term risk, BGNX is less volatile compared to WUXIF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check WUXIF's competition here
BGNX vs ERFSF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ERFSF has a market cap of 14.1B. Regarding current trading prices, BGNX is priced at $0.00, while ERFSF trades at $80.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ERFSF's P/E ratio is 26.93. In terms of profitability, BGNX's ROE is N/A, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, BGNX is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check ERFSF's competition here
BGNX vs BMXMF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, BMXMF has a market cap of 12.4B. Regarding current trading prices, BGNX is priced at $0.00, while BMXMF trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas BMXMF's P/E ratio is 27.10. In terms of profitability, BGNX's ROE is N/A, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, BGNX is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check BMXMF's competition here
BGNX vs SKHHY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SKHHY has a market cap of 7.4B. Regarding current trading prices, BGNX is priced at $0.00, while SKHHY trades at $14.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SKHHY's P/E ratio is 19.17. In terms of profitability, BGNX's ROE is N/A, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, BGNX is less volatile compared to SKHHY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check SKHHY's competition here
BGNX vs SKHCF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SKHCF has a market cap of 7.2B. Regarding current trading prices, BGNX is priced at $0.00, while SKHCF trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SKHCF's P/E ratio is 19.70. In terms of profitability, BGNX's ROE is N/A, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, BGNX is less volatile compared to SKHCF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check SKHCF's competition here
BGNX vs HNGZY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, BGNX is priced at $0.00, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, BGNX's ROE is N/A, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, BGNX is less volatile compared to HNGZY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check HNGZY's competition here
BGNX vs DSRLF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, DSRLF has a market cap of 3.6B. Regarding current trading prices, BGNX is priced at $0.00, while DSRLF trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas DSRLF's P/E ratio is 20.00. In terms of profitability, BGNX's ROE is N/A, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, BGNX and DSRLF have similar daily volatility (0.00).Check DSRLF's competition here
BGNX vs VIMGF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, BGNX is priced at $0.00, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, BGNX's ROE is N/A, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, BGNX is less volatile compared to VIMGF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check VIMGF's competition here
BGNX vs GNTLF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, BGNX is priced at $0.00, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, BGNX's ROE is N/A, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, BGNX and GNTLF have similar daily volatility (0.00).Check GNTLF's competition here
BGNX vs MRCHF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, MRCHF has a market cap of 1.2B. Regarding current trading prices, BGNX is priced at $0.00, while MRCHF trades at $22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas MRCHF's P/E ratio is 52.38. In terms of profitability, BGNX's ROE is N/A, compared to MRCHF's ROE of +0.04%. Regarding short-term risk, BGNX and MRCHF have similar daily volatility (0.00).Check MRCHF's competition here
BGNX vs IDGXF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IDGXF has a market cap of 372M. Regarding current trading prices, BGNX is priced at $0.00, while IDGXF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IDGXF's P/E ratio is 21.33. In terms of profitability, BGNX's ROE is N/A, compared to IDGXF's ROE of +0.28%. Regarding short-term risk, BGNX is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check IDGXF's competition here
BGNX vs EDTXF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, EDTXF has a market cap of 298.7M. Regarding current trading prices, BGNX is priced at $0.00, while EDTXF trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas EDTXF's P/E ratio is -8.48. In terms of profitability, BGNX's ROE is N/A, compared to EDTXF's ROE of +0.88%. Regarding short-term risk, BGNX is less volatile compared to EDTXF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check EDTXF's competition here
BGNX vs AMCY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, BGNX is priced at $0.00, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas AMCY's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to AMCY's ROE of N/A. Regarding short-term risk, BGNX and AMCY have similar daily volatility (0.00).Check AMCY's competition here
BGNX vs NNGRF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, BGNX is priced at $0.00, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, BGNX's ROE is N/A, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, BGNX and NNGRF have similar daily volatility (0.00).Check NNGRF's competition here
BGNX vs DIUXF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, BGNX is priced at $0.00, while DIUXF trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, BGNX's ROE is N/A, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, BGNX is less volatile compared to DIUXF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check DIUXF's competition here
BGNX vs CORBF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, CORBF has a market cap of 127.2M. Regarding current trading prices, BGNX is priced at $0.00, while CORBF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas CORBF's P/E ratio is 2.71. In terms of profitability, BGNX's ROE is N/A, compared to CORBF's ROE of +0.11%. Regarding short-term risk, BGNX and CORBF have similar daily volatility (0.00).Check CORBF's competition here
BGNX vs LDXHF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, LDXHF has a market cap of 114.5M. Regarding current trading prices, BGNX is priced at $0.00, while LDXHF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas LDXHF's P/E ratio is -15.00. In terms of profitability, BGNX's ROE is N/A, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, BGNX is less volatile compared to LDXHF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check LDXHF's competition here
BGNX vs THOXF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, BGNX is priced at $0.00, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas THOXF's P/E ratio is -7.45. In terms of profitability, BGNX's ROE is N/A, compared to THOXF's ROE of -1.67%. Regarding short-term risk, BGNX is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check THOXF's competition here
BGNX vs TIHE Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, BGNX is priced at $0.00, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas TIHE's P/E ratio is 0.32. In terms of profitability, BGNX's ROE is N/A, compared to TIHE's ROE of +0.01%. Regarding short-term risk, BGNX and TIHE have similar daily volatility (0.00).Check TIHE's competition here
BGNX vs PFGTF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, PFGTF has a market cap of 69.8M. Regarding current trading prices, BGNX is priced at $0.00, while PFGTF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas PFGTF's P/E ratio is -3.41. In terms of profitability, BGNX's ROE is N/A, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, BGNX is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check PFGTF's competition here
BGNX vs BIOGF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, BGNX is priced at $0.00, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, BGNX's ROE is N/A, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, BGNX and BIOGF have similar daily volatility (0.00).Check BIOGF's competition here
BGNX vs PCNEF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, BGNX is priced at $0.00, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, BGNX's ROE is N/A, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, BGNX is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check PCNEF's competition here
BGNX vs BMKDF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, BMKDF has a market cap of 44M. Regarding current trading prices, BGNX is priced at $0.00, while BMKDF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas BMKDF's P/E ratio is -41.87. In terms of profitability, BGNX's ROE is N/A, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, BGNX is less volatile compared to BMKDF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check BMKDF's competition here
BGNX vs BIOQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, BIOQ has a market cap of 33.5M. Regarding current trading prices, BGNX is priced at $0.00, while BIOQ trades at $37.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas BIOQ's P/E ratio is 15.83. In terms of profitability, BGNX's ROE is N/A, compared to BIOQ's ROE of +0.01%. Regarding short-term risk, BGNX is less volatile compared to BIOQ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check BIOQ's competition here
BGNX vs SNANF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SNANF has a market cap of 27M. Regarding current trading prices, BGNX is priced at $0.00, while SNANF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SNANF's P/E ratio is -11.80. In terms of profitability, BGNX's ROE is N/A, compared to SNANF's ROE of -10.44%. Regarding short-term risk, BGNX is less volatile compared to SNANF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check SNANF's competition here
BGNX vs ANPCY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, BGNX is priced at $0.00, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, BGNX's ROE is N/A, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, BGNX is less volatile compared to ANPCY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check ANPCY's competition here
BGNX vs PCHM Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, BGNX is priced at $0.00, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas PCHM's P/E ratio is -0.02. In terms of profitability, BGNX's ROE is N/A, compared to PCHM's ROE of +0.25%. Regarding short-term risk, BGNX is less volatile compared to PCHM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check PCHM's competition here
BGNX vs VILGF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, BGNX is priced at $0.00, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas VILGF's P/E ratio is -0.30. In terms of profitability, BGNX's ROE is N/A, compared to VILGF's ROE of N/A. Regarding short-term risk, BGNX and VILGF have similar daily volatility (0.00).Check VILGF's competition here
BGNX vs CLIFF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, BGNX is priced at $0.00, while CLIFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, BGNX's ROE is N/A, compared to CLIFF's ROE of -0.12%. Regarding short-term risk, BGNX is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check CLIFF's competition here
BGNX vs LDDD Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, BGNX is priced at $0.00, while LDDD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas LDDD's P/E ratio is -51.00. In terms of profitability, BGNX's ROE is N/A, compared to LDDD's ROE of -0.28%. Regarding short-term risk, BGNX is less volatile compared to LDDD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check LDDD's competition here
BGNX vs ABDXF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ABDXF has a market cap of 13.3M. Regarding current trading prices, BGNX is priced at $0.00, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, BGNX's ROE is N/A, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, BGNX and ABDXF have similar daily volatility (0.00).Check ABDXF's competition here
BGNX vs IZOZF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IZOZF has a market cap of 11.5M. Regarding current trading prices, BGNX is priced at $0.00, while IZOZF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IZOZF's P/E ratio is -8.50. In terms of profitability, BGNX's ROE is N/A, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, BGNX is less volatile compared to IZOZF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check IZOZF's competition here
BGNX vs IDXG Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IDXG has a market cap of 8.8M. Regarding current trading prices, BGNX is priced at $0.00, while IDXG trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IDXG's P/E ratio is 2.22. In terms of profitability, BGNX's ROE is N/A, compared to IDXG's ROE of +4.85%. Regarding short-term risk, BGNX and IDXG have similar daily volatility (0.00).Check IDXG's competition here
BGNX vs MXDHF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, BGNX is priced at $0.00, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, BGNX's ROE is N/A, compared to MXDHF's ROE of +5.17%. Regarding short-term risk, BGNX and MXDHF have similar daily volatility (0.00).Check MXDHF's competition here
BGNX vs JMPHF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, BGNX is priced at $0.00, while JMPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, BGNX's ROE is N/A, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, BGNX is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check JMPHF's competition here
BGNX vs IMMVF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, BGNX is priced at $0.00, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, BGNX's ROE is N/A, compared to IMMVF's ROE of -5.64%. Regarding short-term risk, BGNX is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check IMMVF's competition here
BGNX vs SQIDF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, BGNX is priced at $0.00, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, BGNX's ROE is N/A, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, BGNX is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check SQIDF's competition here
BGNX vs AVCRF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, AVCRF has a market cap of 5.8M. Regarding current trading prices, BGNX is priced at $0.00, while AVCRF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas AVCRF's P/E ratio is -5.71. In terms of profitability, BGNX's ROE is N/A, compared to AVCRF's ROE of -0.95%. Regarding short-term risk, BGNX is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check AVCRF's competition here
BGNX vs PMSNF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, PMSNF has a market cap of 5.2M. Regarding current trading prices, BGNX is priced at $0.00, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, BGNX's ROE is N/A, compared to PMSNF's ROE of +0.44%. Regarding short-term risk, BGNX and PMSNF have similar daily volatility (0.00).Check PMSNF's competition here
BGNX vs ICBU Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ICBU has a market cap of 4.9M. Regarding current trading prices, BGNX is priced at $0.00, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ICBU's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to ICBU's ROE of -0.22%. Regarding short-term risk, BGNX is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check ICBU's competition here
BGNX vs VRCDF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, BGNX is priced at $0.00, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, BGNX's ROE is N/A, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, BGNX is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check VRCDF's competition here
BGNX vs RNVA Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, BGNX is priced at $0.00, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas RNVA's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to RNVA's ROE of +0.23%. Regarding short-term risk, BGNX and RNVA have similar daily volatility (0.00).Check RNVA's competition here
BGNX vs TDSGF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, TDSGF has a market cap of 4M. Regarding current trading prices, BGNX is priced at $0.00, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas TDSGF's P/E ratio is -4.00. In terms of profitability, BGNX's ROE is N/A, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, BGNX is less volatile compared to TDSGF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check TDSGF's competition here
BGNX vs ANPCF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ANPCF has a market cap of 3.4M. Regarding current trading prices, BGNX is priced at $0.00, while ANPCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ANPCF's P/E ratio is -0.17. In terms of profitability, BGNX's ROE is N/A, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, BGNX is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check ANPCF's competition here
BGNX vs IBXXF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IBXXF has a market cap of 2.2M. Regarding current trading prices, BGNX is priced at $0.00, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IBXXF's P/E ratio is -1.00. In terms of profitability, BGNX's ROE is N/A, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, BGNX is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check IBXXF's competition here
BGNX vs IVRO Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IVRO has a market cap of 1.8M. Regarding current trading prices, BGNX is priced at $0.00, while IVRO trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IVRO's P/E ratio is -0.89. In terms of profitability, BGNX's ROE is N/A, compared to IVRO's ROE of +0.06%. Regarding short-term risk, BGNX and IVRO have similar daily volatility (0.00).Check IVRO's competition here
BGNX vs CHHL Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, BGNX is priced at $0.00, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas CHHL's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to CHHL's ROE of +0.00%. Regarding short-term risk, BGNX is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check CHHL's competition here
BGNX vs SLDX Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SLDX has a market cap of 1.6M. Regarding current trading prices, BGNX is priced at $0.00, while SLDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SLDX's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to SLDX's ROE of +0.14%. Regarding short-term risk, BGNX is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check SLDX's competition here
BGNX vs DIGP Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, BGNX is priced at $0.00, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas DIGP's P/E ratio is -1.04. In terms of profitability, BGNX's ROE is N/A, compared to DIGP's ROE of +1.19%. Regarding short-term risk, BGNX is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check DIGP's competition here
BGNX vs EPGNF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, BGNX is priced at $0.00, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, BGNX's ROE is N/A, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, BGNX and EPGNF have similar daily volatility (0.00).Check EPGNF's competition here
BGNX vs RSHN Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, BGNX is priced at $0.00, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas RSHN's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to RSHN's ROE of -5.42%. Regarding short-term risk, BGNX and RSHN have similar daily volatility (0.00).Check RSHN's competition here
BGNX vs IDTA Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IDTA has a market cap of 708K. Regarding current trading prices, BGNX is priced at $0.00, while IDTA trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IDTA's P/E ratio is 8.75. In terms of profitability, BGNX's ROE is N/A, compared to IDTA's ROE of +0.13%. Regarding short-term risk, BGNX is less volatile compared to IDTA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check IDTA's competition here
BGNX vs SZLSF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, BGNX is priced at $0.00, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, BGNX's ROE is N/A, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, BGNX is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check SZLSF's competition here
BGNX vs SCRSF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, BGNX is priced at $0.00, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, BGNX's ROE is N/A, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, BGNX and SCRSF have similar daily volatility (0.00).Check SCRSF's competition here
BGNX vs NSTM Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, BGNX is priced at $0.00, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas NSTM's P/E ratio is 0.20. In terms of profitability, BGNX's ROE is N/A, compared to NSTM's ROE of -0.83%. Regarding short-term risk, BGNX is less volatile compared to NSTM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check NSTM's competition here
BGNX vs MBGNF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, BGNX is priced at $0.00, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, BGNX's ROE is N/A, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, BGNX is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check MBGNF's competition here
BGNX vs NVTAQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, BGNX is priced at $0.00, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, BGNX's ROE is N/A, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, BGNX is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check NVTAQ's competition here
BGNX vs ARYC Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ARYC has a market cap of 79.3K. Regarding current trading prices, BGNX is priced at $0.00, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ARYC's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to ARYC's ROE of +0.55%. Regarding short-term risk, BGNX is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check ARYC's competition here
BGNX vs HCLC Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, BGNX is priced at $0.00, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas HCLC's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to HCLC's ROE of +0.11%. Regarding short-term risk, BGNX and HCLC have similar daily volatility (0.00).Check HCLC's competition here
BGNX vs MEDD Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, MEDD has a market cap of 63.8K. Regarding current trading prices, BGNX is priced at $0.00, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas MEDD's P/E ratio is -0.02. In terms of profitability, BGNX's ROE is N/A, compared to MEDD's ROE of +0.74%. Regarding short-term risk, BGNX is less volatile compared to MEDD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check MEDD's competition here
BGNX vs IHTI Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, IHTI has a market cap of 32.5K. Regarding current trading prices, BGNX is priced at $0.00, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas IHTI's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to IHTI's ROE of +0.00%. Regarding short-term risk, BGNX is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check IHTI's competition here
BGNX vs TOMDF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, BGNX is priced at $0.00, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas TOMDF's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, BGNX is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check TOMDF's competition here
BGNX vs CGNH Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, BGNX is priced at $0.00, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas CGNH's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to CGNH's ROE of +1.41%. Regarding short-term risk, BGNX and CGNH have similar daily volatility (0.00).Check CGNH's competition here
BGNX vs ABMC Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, BGNX is priced at $0.00, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ABMC's P/E ratio is 0.01. In terms of profitability, BGNX's ROE is N/A, compared to ABMC's ROE of +0.86%. Regarding short-term risk, BGNX and ABMC have similar daily volatility (0.00).Check ABMC's competition here
BGNX vs CYPS Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, BGNX is priced at $0.00, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas CYPS's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to CYPS's ROE of N/A. Regarding short-term risk, BGNX and CYPS have similar daily volatility (0.00).Check CYPS's competition here
BGNX vs RGDXQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, BGNX is priced at $0.00, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, BGNX is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check RGDXQ's competition here
BGNX vs DMTKQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, BGNX is priced at $0.00, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, BGNX's ROE is N/A, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, BGNX and DMTKQ have similar daily volatility (0.00).Check DMTKQ's competition here
BGNX vs MEDVF Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, BGNX is priced at $0.00, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas MEDVF's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, BGNX is less volatile compared to MEDVF. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check MEDVF's competition here
BGNX vs BIOCQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, BIOCQ has a market cap of 2.6K. Regarding current trading prices, BGNX is priced at $0.00, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, BGNX is less volatile compared to BIOCQ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check BIOCQ's competition here
BGNX vs GWHP Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, BGNX is priced at $0.00, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas GWHP's P/E ratio is -0.00. In terms of profitability, BGNX's ROE is N/A, compared to GWHP's ROE of +6.19%. Regarding short-term risk, BGNX is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check GWHP's competition here
BGNX vs ROSGQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, BGNX is priced at $0.00, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, BGNX and ROSGQ have similar daily volatility (0.00).Check ROSGQ's competition here
BGNX vs HTGMQ Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, BGNX is priced at $0.00, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, BGNX and HTGMQ have similar daily volatility (0.00).Check HTGMQ's competition here
BGNX vs OPGX Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, OPGX has a market cap of 17. Regarding current trading prices, BGNX is priced at $0.00, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas OPGX's P/E ratio is -0.00. In terms of profitability, BGNX's ROE is N/A, compared to OPGX's ROE of +0.46%. Regarding short-term risk, BGNX is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNX.Check OPGX's competition here
BGNX vs MRPS Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, MRPS has a market cap of 0. Regarding current trading prices, BGNX is priced at $0.00, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas MRPS's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to MRPS's ROE of N/A. Regarding short-term risk, BGNX and MRPS have similar daily volatility (0.00).Check MRPS's competition here
BGNX vs EPGNY Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, BGNX is priced at $0.00, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, BGNX's ROE is N/A, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, BGNX and EPGNY have similar daily volatility (0.00).Check EPGNY's competition here
BGNX vs AGHC Comparison April 2026
BGNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNX stands at 0. In comparison, AGHC has a market cap of 0. Regarding current trading prices, BGNX is priced at $0.00, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNX currently has a P/E ratio of N/A, whereas AGHC's P/E ratio is N/A. In terms of profitability, BGNX's ROE is N/A, compared to AGHC's ROE of +2.90%. Regarding short-term risk, BGNX and AGHC have similar daily volatility (0.00).Check AGHC's competition here